Application of combination of semeglutide and sodium butyrate in preparation of medicine for reducing weight
By combining smegglutide with sodium butyrate, the problems of poor efficacy and significant side effects of smegglutide in weight loss treatment have been solved, achieving better weight loss results and fewer side effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-01-20
- Publication Date
- 2026-03-13
AI Technical Summary
The existing GLP-1 receptor agonist semaglutide has problems in weight loss treatment, such as difficulty in maintaining efficacy, large side effects, and limited efficacy.
Smegglutide was used in combination with sodium butyrate at doses of 35-45 μg/kg and 1-2 g/kg, respectively, to enhance the weight loss effect. Smegglutide was administered once every two days, and sodium butyrate once daily.
It significantly enhances weight loss effects, reduces side effects, improves treatment effectiveness, and avoids the development of drug resistance.
Smart Images
Figure CN121648265A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical technology, specifically to the application of smegglutide in combination with sodium butyrate in the preparation of drugs for weight loss. Background Technology
[0002] Obesity is a sub-healthy state caused by a combination of genetic, environmental, and behavioral factors, characterized by a persistent excess of energy intake over expenditure, leading to excessive accumulation of body fat. The World Health Organization has recognized obesity as one of the most important chronic public health problems globally. Obesity is also a significant risk factor for various complications such as type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and cardiovascular disease. Therefore, developing safe and effective weight loss therapies has significant clinical and social implications.
[0003] Smegglutide, a long-acting GLP-1 receptor agonist, is widely used in clinical weight loss treatment with significant effects, but it still has several limitations: First, its efficacy varies from person to person, with most patients failing to achieve their ideal weight loss goals, and weight rebound is common after discontinuation; second, the drug is often accompanied by gastrointestinal side effects such as nausea, vomiting, and diarrhea; furthermore, as a single-target drug, smegglutide has limited effectiveness in significantly increasing energy expenditure and specifically reducing visceral fat. Therefore, there is an urgent need to develop novel weight loss strategies with better efficacy, fewer side effects, and synergistic effects through multiple targets.
[0004] Butyrate, a major component of short-chain fatty acids, has been shown to improve diet-induced obesity-related glucose and lipid metabolism disorders. Specifically, sodium butyrate can promote the activation of brown adipocytes and the browning of white adipocytes, thereby increasing energy expenditure and improving insulin resistance, fatty liver, and intestinal dysfunction. Based on this, this invention proposes a drug to significantly enhance the weight-loss effect of smegglutide. Summary of the Invention
[0005] In order to overcome the shortcomings of existing technologies, such as poor efficacy and large side effects when semaglutide is used alone, the primary objective of this invention is to provide the application of semaglutide in combination with sodium butyrate in the preparation of drugs for weight loss, which has broad prospects.
[0006] A second object of the present invention is to provide the use of a composition containing smegglutinin and sodium butyrate in the preparation of a medicament for weight loss.
[0007] The third objective of this invention is to provide a non-therapeutic weight loss method that can improve the therapeutic efficacy of semaglutide, reduce the incidence of side effects, and delay or avoid the development of drug resistance.
[0008] To achieve the above objectives, the technical solution adopted by the present invention is as follows: Application of smegglutide in combination with sodium butyrate in the preparation of drugs for weight loss.
[0009] This invention addresses the problems of maintaining the weight loss efficacy and gastrointestinal side effects of the existing GLP-1 receptor agonist semaglutide by combining it with sodium butyrate.
[0010] Furthermore, the dosage of smegglutide is 35-45 μg / kg; the dosage of sodium butyrate is 1-2 g / kg.
[0011] Furthermore, the dosage of smegglutide is 40 μg / kg; the dosage of sodium butyrate is 1 g / kg.
[0012] Furthermore, the combination of smegglutinin and sodium butyrate can control weight and suppress appetite.
[0013] The use of a composition containing smegglutide and sodium butyrate in the preparation of a medicament for weight loss.
[0014] A non-therapeutic weight loss method involves administering sodium butyrate once daily and smegglutide every two days to the individual who needs to lose weight.
[0015] Furthermore, the target of the weight loss is a mammal.
[0016] The beneficial technical effects of this invention are as follows: This invention combines semaglutide with sodium butyrate, which synergistically enhances appetite suppression, significantly reduces body weight and fat mass in mice, and achieves better weight loss than semaglutide monotherapy. The combination of semaglutide and sodium butyrate provides a novel strategy for the treatment of obesity with superior efficacy and tolerability. Attached Figure Description
[0017] Figure 1 The graph shows the changes in body weight and cumulative food intake of mice in each group after injection of different doses of sodium butyrate. In the graph, A shows the changes in body weight of mice in each group, and B shows the cumulative food intake of mice in each group.
[0018] Figure 2 Figure showing the changes in body weight of mice after 12 weeks of feeding with normal and high-fat diets; Figure 3 The graph shows the body weight and weight change of mice in each group. In the graph, A is the body weight result of each group of mice during the experiment, B is the body weight result of each group of mice after the experiment, C is the weight change result of each group of mice during the experiment, and D is the weight change result of each group of mice after the experiment (* represents p<0.05). Figure 4The graph shows the changes in fat mass and lean mass of mice in each group before and after the experiment. In the graph, A is the result of fat mass of mice in each group before and after the experiment, B is the result of the change in fat mass of mice in each group after the experiment, C is the result of lean mass of mice in each group before and after the experiment, and D is the result of the change in lean mass of mice in each group after the experiment. Figure 5 The graph shows the changes in food intake of mice in each group before and after the experiment; in the graph, A is the result of food intake of mice in each group during the experiment, and B is the average food intake of mice in each group after the experiment. Detailed Implementation The following is a further detailed description of the present invention in conjunction with specific preferred embodiments, and it should not be construed that the specific implementation of the present invention is limited to these descriptions. For those skilled in the art, various simple deductions or substitutions can be made without departing from the concept of the present invention, and all such modifications and substitutions should be considered within the scope of protection of the present invention. Specific conditions not specified in the embodiments are performed according to conventional conditions or conditions recommended by the manufacturer. Unless otherwise specified, all reagents or instruments used are conventional products obtained through commercial channels.
[0019] The C57BL / 6 mice used in this invention were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.; the normal diet (22.47% protein, 12.11% fat, 65.42% carbohydrates) was purchased from Beijing Huafukang Biotechnology Co., Ltd., Cat#1022; the high-fat diet (20% protein, 60% fat, 20% carbohydrates) was purchased from Jiangsu Medison Biomedical Co., Ltd., Cat#MD12033.
[0020] Example 1 The weight loss effect of sodium butyrate was investigated, as follows: 1.1 Building the Model Forty-five 8-week-old male C57BL / 6 mice were used and acclimatized for one week before the experiment. Ten mice were randomly selected and fed a normal diet (normal control group), while the remaining mice were fed a diet containing 60% high-fat. All mice had free access to food and water. The model was considered successfully established when the average body weight of the high-fat diet group was significantly higher than that of the normal diet group by more than 20-25%.
[0021] 1.2 Experimental Grouping Before the experiment, the weight and body composition of obese mice were measured, and they were randomly divided into three groups according to their weight and fat weight, with 10 mice in each group: model group (physiological saline), group 1 (sodium butyrate, 0.5 g / kg), and group 2 (sodium butyrate, 1 g / kg). All mice were housed in individual cages.
[0022] 1.3 Administration method During the experiment, the food intake and body weight of each mouse were recorded before lights out (19:00) each day, and then medication was administered as follows: Model group: Administered an equal volume of normal saline by gavage once daily for 4 consecutive days; Group 1: Subcutaneous injection of 0.5 g / kg sodium butyrate, once a day for 4 consecutive days; Group 2: 1 g / kg sodium butyrate was injected subcutaneously once a day for 4 consecutive days.
[0023] 1.4 Observation Indicators Four days later, the body weight and cumulative food intake of mice in each group were recorded. The results are shown in [link to data]. Figure 1 .
[0024] Figure 1 The figures show the changes in body weight and cumulative food intake of mice in each group after injection of different doses of sodium butyrate. In the figures, A represents the changes in body weight of mice in each group, and B represents the cumulative food intake of mice in each group. Figure 1 It can be seen that a dose of 1 g / kg of sodium butyrate can significantly reduce the body weight and food intake of mice.
[0025] Example 2 The weight loss effect of semaglutide combined with sodium butyrate was investigated, as follows: 2.1 Constructing an obesity model Fifty-five 8-week-old male C57BL / 6 mice were used and acclimatized for one week before the experiment. Ten mice were randomly selected and fed a normal diet (normal control group), while the remaining mice were fed a diet containing 60% high-fat. All mice had free access to food and water. The model was considered successfully established when the average body weight of the high-fat diet group was significantly higher than that of the normal diet group by 20-25%. Figure 2 As shown.
[0026] 2.2 Experimental Grouping Before the experiment, the weight and body composition of obese mice were measured, and they were randomly divided into four groups of 10 mice each according to their weight and fat weight: model group (physiological saline), experimental group 1 (40 μg / kg smegglutide + 1 g / kg sodium butyrate), experimental group 2 (40 μg / kg smegglutide) and experimental group 3 (1 g / kg sodium butyrate). All mice were housed individually.
[0027] 2.3 Administration method During the experiment, the food intake and body weight of each mouse were recorded before lights out (19:00) each day, and then medication was administered as follows: Model group: The same volume of normal saline was administered by gavage once a day for 14 consecutive days; Experimental Group 1: Subcutaneous injection of smegglutide once every two days and sodium butyrate once a day for 14 consecutive days; Experimental Group 2: Smegglutide was administered subcutaneously every two days for 14 consecutive days; Experimental Group 3: Sodium butyrate was injected subcutaneously once a day for 14 consecutive days.
[0028] 2.4 Observation Indicators Fourteen days later, the fat weight and lean body weight of mice in each group were measured. The results are shown in [link to data]. Figure 3-5 And Table 1.
[0029] Table 1. Results of body weight, fat mass, lean body mass, and food intake of mice in each group after 14 days. Figure 3 The figures show the body weight and weight changes of mice in each group. In the figures, A shows the body weight of mice in each group during the experiment, B shows the body weight of mice in each group after the experiment, C shows the weight changes of mice in each group during the experiment, and D shows the weight changes of mice in each group after the experiment (* represents p<0.05). Figure 4 The graphs show the changes in fat mass and lean mass of mice in each group before and after the experiment. In the graphs, A shows the results of fat mass in each group of mice before and after the experiment, B shows the changes in fat mass in each group of mice after the experiment, C shows the results of lean mass in each group of mice before and after the experiment, and D shows the changes in lean mass in each group of mice after the experiment. Figure 5 The graph shows the changes in food intake of mice in each group before and after the experiment. In the graph, A shows the food intake of mice in each group during the experiment, and B shows the average food intake of mice in each group after the experiment. Figure 3-5 It can be seen that, compared with the model group, although experimental groups 2 and 3 all reduced mouse body weight, food intake, and fat mass, the effect was not as significant as that of experimental group 1. These results indicate that the combined use of smegglutide and sodium butyrate can enhance the weight-loss effect of smegglutide.
[0030] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them. The basic principles and main features of the present invention have been described above with specific implementation schemes. Based on the present invention, some modifications or substitutions can be made, but these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of protection claimed by the present invention.
Claims
1. Application of smegglutide in combination with sodium butyrate in the preparation of drugs for weight loss.
2. The application of smegglutide combined with sodium butyrate according to claim 1 in the preparation of a drug for weight loss, characterized in that, The dosage of the smegglutinin is 35-45 μg / kg; the dosage of the sodium butyrate is 1-2 g / kg.
3. The application of smegglutide combined with sodium butyrate according to claim 2 in the preparation of a drug for weight loss, characterized in that, The dosage of the smegglutinin is 40 μg / kg; the dosage of the sodium butyrate is 1 g / kg.
4. The use of semaglutide in combination with sodium butyrate according to claim 1 in the preparation of a drug for weight loss, wherein the combination of semaglutide and sodium butyrate can control weight and suppress appetite.
5. Use of compositions containing smegglutide and sodium butyrate in the preparation of medicaments for weight loss.
6. A non-therapeutic weight loss method, characterized in that, Individuals who need to lose weight should be given sodium butyrate once a day and smegglutide once every two days.
7. The non-therapeutic weight loss method according to claim 6, characterized in that, The subjects of the weight loss program are mammals.